As bleak as it sounds? Analysing trends in oncology clinical trial initiation in the UK from 2010 to 2022
The UK's trends in phase III oncology clinical trial initiation from 2010 to 2022 largely reflects global trends, suggesting that other factors (eg, COVID-19 pandemic) beyond Brexit, may have had a stronger influence on clinical trial initiation within the UK.
Authors
- Dario Trapani (ORCID: https://orcid.org/0000-0003-1672-9560)
- Jeremy L. Warner (ORCID: https://orcid.org/0000-0002-2851-7242)
- Matthew J. Hadfield (ORCID: https://orcid.org/0000-0002-8768-0082)
- Mark P. Lythgoe (ORCID: https://orcid.org/0000-0002-8952-7639)
- Alexander D. VanHelene (ORCID: https://orcid.org/0009-0001-6197-949X)
Institutions
- University of Milan (IT)
- Brown University (US)
- Rhode Island Hospital (US)
- Hammersmith Hospital (GB)
- Lifespan (US)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- European Institute of Oncology (IT)
Publication Details
- Journal
- BMJ Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/bmjonc-2024-000410
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- National Cancer Institute